We give you a written timeline estimate for your case before you commit.Ask about treatment
Cystic fibrosis (CF): US-approved treatments and how families in the Gulf can access them
A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Cystic fibrosis: the short answer
The US FDA has approved five medicines covered on this page for cystic fibrosis, each for a specific group of patients: Trikafta, Alyftrek, Kalydeco, Orkambi and Pulmozyme. On 17 October 2026, five of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Trikafta, Alyftrek, Kalydeco, Orkambi and Pulmozyme.
- Gulf registers (checked 17 October 2026): see each medicine below.
- Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is cystic fibrosis?
Cystic fibrosis is an inherited disease in which the body makes thick, sticky mucus that can damage many organs. The mucus can clog the airways, leading to breathing problems and lung infections that cause chronic coughing, wheezing and inflammation. Over time this can cause permanent lung damage.[1]
Most people with cystic fibrosis also have digestive problems, because thick mucus builds up in the pancreas. Some babies have a blockage of the intestine shortly after birth, called meconium ileus.[1]
Cystic fibrosis is caused by variants in the CFTR gene. It occurs in 1 in 2,500 to 3,500 white newborns in the United States and is less common in other groups. Some US-approved medicines, such as Trikafta, are indicated only for people with at least one responsive CFTR variant.[1, 2]
Cystic fibrosis in the Gulf
Cystic fibrosis in Saudi Arabia was described as early as 1989 in the European Journal of Pediatrics, and carrier screening practices, including in the Gulf, were reviewed internationally in 2020.[3, 4]
We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 0 of 5 were listed in Saudi Arabia and 5 of 5 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[5, 6]
US FDA-approved medicines for cystic fibrosis
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Trikafta (elexacaftor, tezacaftor and ivacaftor)
US FDA-approved for cystic fibrosis in adults and children 2 years and older with at least one CFTR variant that is responsive to it based on clinical or laboratory data. It is taken by mouth.[2]
Current US label version: 22 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Kuwait, Qatar - Alyftrek (vanzacaftor, tezacaftor and deutivacaftor)
US FDA-approved for cystic fibrosis in adults and children 6 years and older with at least one responsive CFTR variant. It is a once-daily tablet.[7]
Current US label version: 26 August 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Qatar, Bahrain, Egypt, India - Kalydeco (ivacaftor)
US FDA-approved for cystic fibrosis in patients 1 month and older with at least one CFTR mutation responsive to ivacaftor. It is taken by mouth.[8]
Current US label version: 23 March 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Egypt, India, Pakistan - Orkambi (lumacaftor and ivacaftor)
US FDA-approved for cystic fibrosis in patients 1 year and older who have two copies of the F508del mutation. It is taken by mouth.[9]
Current US label version: 24 March 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, Egypt, India, Pakistan - Pulmozyme (dornase alfa)
US FDA-approved for improving lung function in children and adults with cystic fibrosis, together with standard therapies. It is inhaled through a nebulizer.[10]
Current US label version: 17 December 2025. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
Country access guides: Saudi Arabia, UAE, India
How families in the Gulf can access treatment
If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[11, 12] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
- Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for cystic fibrosis
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for cystic fibrosis?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Trikafta, Alyftrek, Kalydeco, Orkambi and Pulmozyme. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Trikafta available in Saudi Arabia or the UAE?
We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.
How can a family in the Gulf get Trikafta?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Does Reserve Meds diagnose or prescribe?
No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.
Which CFTR modulator fits my child?
It depends on the CFTR variants found on genetic testing and on age. Each US label lists the responsive variants. Your CF team checks this before prescribing.
Sources for the condition-specific answers: [2, 8, 9]
Sources
Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.
- MedlinePlus Genetics (US National Library of Medicine): Cystic fibrosis
- DailyMed: TRIKAFTA (elexacaftor, tezacaftor and ivacaftor) US prescribing information, label version 22 June 2026
- Nazer H, et al. Cystic fibrosis in Saudi Arabia. Eur J Pediatr. 1989 (PubMed 2785036)
- Delatycki MB, et al. International perspectives on the implementation of reproductive carrier screening. Prenat Diagn. 2020 (PubMed 31774570)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed: ALYFTREK (vanzacaftor, tezacaftor and deutivacaftor) US prescribing information, label version 26 August 2026
- DailyMed: KALYDECO (ivacaftor) US prescribing information, label version 23 March 2026
- DailyMed: ORKAMBI (lumacaftor and ivacaftor) US prescribing information, label version 24 March 2026
- DailyMed: PULMOZYME (dornase alfa) US prescribing information, label version 17 December 2025
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- COPD
- Invasive fungal infections
- Trikafta: drug overview
- Alyftrek: drug overview
- Kalydeco: drug overview
- Named-patient access in the Gulf, explained
- US-approved medicines not yet registered in the Gulf
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
- یہ صفحہ اردو میں پڑھیں
This page is general health information, not medical advice. It does not replace a consultation with your doctor.